Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Apr;31(4):1246-1256.
doi: 10.1038/s41591-024-03484-8. Epub 2025 Feb 5.

First-in-human study of epidural spinal cord stimulation in individuals with spinal muscular atrophy

Affiliations
Clinical Trial

First-in-human study of epidural spinal cord stimulation in individuals with spinal muscular atrophy

Genís Prat-Ortega et al. Nat Med. 2025 Apr.

Abstract

Spinal muscular atrophy (SMA) is an inherited neurodegenerative disease causing motoneuron dysfunction, muscle weakness, fatigue and early mortality. Three new therapies can slow disease progression, enabling people to survive albeit with lingering motor impairments. Indeed, weakness and fatigue are still among patients' main concerns. Here we show that epidural spinal cord stimulation (SCS) improved motoneuron function, thereby increasing strength, endurance and gait quality, in three adults with type 3 SMA. Preclinical works demonstrated that SMA motoneurons show low firing rates because of a loss of excitatory input from primary sensory afferents. In the present study, we hypothesized that correcting this loss with electrical stimulation of the sensory afferents could improve motoneuron function. To test this hypothesis, we implanted three adults with SMA with epidural electrodes over the lumbosacral spinal cord, targeting sensory axons of the legs. We delivered SCS for 4 weeks, 2 h per day during motor tasks. Our intervention led to improvements in strength (up to +180%), gait quality (mean step length: +40%) and endurance (mean change in 6-minute walk test: +26 m), paralleled by increased motoneuron firing rates. These changes persisted even when SCS was turned OFF. Notably, no adverse events related to the stimulation were reported. ClinicalTrials.gov identifier: NCT05430113 .

PubMed Disclaimer

Conflict of interest statement

Competing interests: This study was supported by an exploratory research grant from F. Hoffmann-La Roche to M.C., and Genentech and the University of Pittsburgh hold rights to intellectual property related to this study. M.C., G.P.O. and M.J.L.E. hold patent applications that relate to this work. The remaining authors declare no competing interests.

References

    1. Yasuda, T., Nakata, Y. & Mochizuki, H. α-Synuclein and neuronal cell death. Mol. Neurobiol. 47, 466–483 (2013). - PubMed - DOI
    1. Saxena, S. & Caroni, P. Selective neuronal vulnerability in neurodegenerative diseases: from stressor thresholds to degeneration. Neuron 71, 35–48 (2011). - PubMed - DOI
    1. Blesa, J. & Przedborski, S. Parkinson’s disease: animal models and dopaminergic cell vulnerability. Front. Neuroanat. 8, 155 (2014). - PubMed - PMC - DOI
    1. Friedlander, R. M., Brown, R. H., Gagliardini, V., Wang, J. & Yuan, J. Inhibition of ICE slows ALS in mice. Nature 388, 31–31 (1997). - PubMed - DOI
    1. Ona, V. O. et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington’s disease. Nature 399, 263–267 (1999). - PubMed - DOI

Publication types

Associated data